Literature DB >> 2548963

Combination therapy for systemic mycosis.

A Polak1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2548963     DOI： 10.1007/BF01639520

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  19 in total

1.  Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.

Authors:  A Polak
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

2.  Experience with itraconazole in deep mycoses in northern Italy.

Authors:  M A Viviani; A M Tortorano; R Woenstenborghs; G Cauwenbergh
Journal:  Mykosen       Date:  1987-05

Review 3.  [5-Fluorocytosine and combinations].

Authors:  A Polak
Journal:  Ann Biol Clin (Paris)       Date:  1987       Impact factor: 0.459

4.  A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis.

Authors:  D Borelli
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

5.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

Authors:  A M Sugar; C Saunders
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

6.  Ketoconazole and flucytosine alone and in combination against Candida spp. in a neutropenic site in rabbits.

Authors:  C E Hughes; L R Peterson; W H Beggs; D N Gerding
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

7.  Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity.

Authors:  J E Baley; R M Kliegman; A A Fanaroff
Journal:  Pediatrics       Date:  1984-02       Impact factor: 7.124

8.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

9.  Four outbreaks of nosocomial systemic candidiasis.

Authors:  J P Burnie; R Matthews; W Lee; J Philpott-Howard; R Brown; N Damani; J Breuer; K Honeywell; Z Jordans
Journal:  Epidemiol Infect       Date:  1987-08       Impact factor: 2.451

10.  Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia.

Authors:  M Thaler; J Bacher; T O'Leary; P A Pizzo
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226
View more
  10 in total

1.  Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine.

Authors:  M A Ghannoum; B Elewski
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models.

Authors:  H Sanati; C F Ramos; A S Bayer; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Hepatosplenic candidasis, a fatal disease?

Authors:  A Loeliger; M van Leeuwen; M Rozenberg-Arska; A W Dekker
Journal:  Infection       Date:  1992-11       Impact factor: 3.553

4.  In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

Authors:  M A Pfaller; S A Messer; L Boyken; H Huynh; R J Hollis; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.

Authors:  D Andes; M van Ogtrop
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients.

Authors:  M Abele-Horn; A Kopp; U Sternberg; A Ohly; A Dauber; W Russwurm; W Büchinger; O Nagengast; P Emmerling
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

7.  Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphotericin B on Candida albicans.

Authors:  G M Scalarone; Y Mikami; N Kurita; K Yazawa; M Miyaji
Journal:  Mycopathologia       Date:  1992-12       Impact factor: 2.574

8.  Tibial osteomyelitis due to Aspergillus flavus in a heart transplant patient.

Authors:  D De Vuyst; I Surmont; J Verhaegen; J Vanhaecke
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

9.  Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients.

Authors:  P E Verweij; J P Donnelly; B J Kullberg; J F Meis; B E De Pauw
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

10.  Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro.

Authors:  M Scheven; F Schwegler
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.